Most Read Articles
Pearl Toh, 5 days ago
Mepolizumab added on to standard of care for patients with severe eosinophilic asthma better improves health-related quality of life (HRQOL), along with improved asthma symptoms and lung function compared with placebo, according to the MUSCA* study.
Pearl Toh, 4 days ago
Treatment with abiraterone acetate and prednisone for metastatic prostate cancer (mPC) in patients who responded poorly to initial androgen-deprivation therapy (ADT) showed encouraging results with favourable overall survival (OS) to historical controls, although the prespecified criteria for a positive result was not met , according to the S1014* trial.
3 days ago
Blood pressure (BP) ≥140/90 mm Hg appears to increase the risk of maternal complications and adverse foetal outcomes, irrespective of the number of medications used, a study suggests. However, the greatest risk is observed among pregnant women taking multiple agents and whose BP levels are within the aforementioned range.
5 days ago
Relapse after randomization is more likely to occur in patients with severe baseline hallucinations, reports a new study. In addition, the presence of baseline hallucinations is associated with a greater risk of relapse after discontinuation of risperidone vs continued risperidone treatment.

SGLT-2 inhibitors cut risk of hospitalization for HF, death in real-world study

Elvira Manzano
23 days ago
Dr Mikhail Kosiborod

Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.

Overall, there were 734 new hHF cases (incidence rate 0.41/100 person years). New users of SGLT-2 inhibitors (dapagliflozin, canagliflozin and empagliflozin) had a 39 percent lower rate of incident hHF vs new users of other glucose-lowering drugs (pooled hazard ratio [HR, 0.61; p<0.001). Similarly, rate of death from any cause (HR, 0.49; p<0.001) was lower with the SGLT-2 inhibitors as was the composite endpoint of hHF and death from any cause (HR, 0.54; p<0.001). [ACC.17, abstract 415-14]

The cardiovascular benefits appeared to be class-related than compound-specific, said lead investigator Dr Mikhail Kosiborod from the University of Missouri-Kansas City School of Medicine, Kansas City, US.

 “There was no significant heterogeneity across countries despite geographic variations in use of SGLT-2 inhibitors [canagliflozin was predominantly used in the US, dapagliflozin in Europe],” he said. “This was in a broad population of patients in general practice with type 2 diabetes [T2D], the overwhelming majority of whom did not have known cardiovascular disease [CVD].”

The researchers compared the risk of hHF, all-cause death, and the composite of hHF and death in over 300,000 patients with T2D who were newly prescribed SGLT-2 inhibitors (n=154,523) or other glucose-lowering drugs (n=154,523). Data from large registries of patients across six countries (US, Germany, Sweden, Norway, Denmark, and the UK) were pooled and analysed.

Nonparsimonious propensity scores for initiation of SGLT-2 inhibitors were used to match the two treatment groups. At baseline, 80 percent of the patients were receiving an antihypertensive, 67 percent were on a statin, and almost 80 percent were on metformin therapy. The mean age of the patients was 57; 44 percent were women.

Most patients in the US were treated with canagliflozin (75.9 percent) while almost all patients in Europe received dapagliflozin (91.9 percent). Overall, 52.7 percent of the patients were treated with canagliflozin, 41.8 with dapagliflozin, and 5.5 percent with empagliflozin.

In this large multicountry cohort, treatment with SGLT-2 inhibitors was associated with marked and highly significant reductions in HHF and death. “This is interesting as what you’re seeing in terms of HF hospitalization is primarily a heart-prevention signal rather than a heart-treatment signal,” Kosiborod said.

SGLT-2 inhibitors cut risk of hospitalization for HF, death in real-world study

“I believe this class [SGLT-2 inhibitor] has a really remarkable potential to transform how we manage diabetes and patient outcomes,” he added, suggesting that more data from multiple sources are warranted to drive the message home.

In the meantime, cardiologists await with enthusiasm the results of the ongoing CV safety studies with canagliflozin (CANVAS) and dapagliflozin (DECLARE-TIMI 58) to establish whether the benefits observed with SGLT-2 inhibitors are indeed a class-effect of the drugs.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Mepolizumab added on to standard of care for patients with severe eosinophilic asthma better improves health-related quality of life (HRQOL), along with improved asthma symptoms and lung function compared with placebo, according to the MUSCA* study.
Pearl Toh, 4 days ago
Treatment with abiraterone acetate and prednisone for metastatic prostate cancer (mPC) in patients who responded poorly to initial androgen-deprivation therapy (ADT) showed encouraging results with favourable overall survival (OS) to historical controls, although the prespecified criteria for a positive result was not met , according to the S1014* trial.
3 days ago
Blood pressure (BP) ≥140/90 mm Hg appears to increase the risk of maternal complications and adverse foetal outcomes, irrespective of the number of medications used, a study suggests. However, the greatest risk is observed among pregnant women taking multiple agents and whose BP levels are within the aforementioned range.
5 days ago
Relapse after randomization is more likely to occur in patients with severe baseline hallucinations, reports a new study. In addition, the presence of baseline hallucinations is associated with a greater risk of relapse after discontinuation of risperidone vs continued risperidone treatment.